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Abstract
Experimental studies on hepatitis B virus (HBV) replication are commonly done with human hepatoma cells to reflect the
natural species and tissue tropism of the virus. However, HBV can also replicate, upon transfection of virus coding plasmids,
in cells of other species. In such cross-species transfection experiments with chicken LMH hepatoma cells, we previously
observed the formation of HBV genomes with aberrant electrophoretic mobility, in addition to the those DNA species
commonly seen in human HepG2 hepatoma cells. Here, we report that these aberrant DNA forms are mainly due to
excessive splicing of HBV pregenomic RNA and the abundant synthesis of spliced DNA products, equivalent to those also
made in human cells, yet at much lower level. Mutation of the common splice acceptor site abolished splicing and in turn
enhanced production of DNA from full-length pgRNA in transfected LMH cells. The absence of splicing made other DNA
molecules visible, that were shortened due to the lack of sequences in the core protein coding region. Furthermore, there
was nearly full-length DNA in the cytoplasm of LMH cells that was not protected in viral capsids. Remarkably, we have
previously observed similar shortened genomes and non-protected viral DNA in human HepG2 cells, yet exclusively in the
nucleus where uncoating and final release of viral genomes occurs. Hence, two effects reflecting capsid disassembly in the
nucleus in human HepG2 cells are seen in the cytoplasm of chicken LMH cells.
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Introduction
Hepatitis B virus (HBV) primarily infects humans and virus
amplification takes place exclusively in the liver. To reflect this
tight species and tissue tropism, studies of HBV replication are
commonly done with human HepG2 or HuH-7 hepatoma cells
[1,2]. Both cell lines are not susceptible to HBV infection but they
support the synthesis of virus particles upon transfection of viral
genome containing plasmids. Assembly of HBV capsids occurs in
the cytoplasm and starts with packaging of viral polymerase and
pregenomic RNA (pgRNA) by newly made core proteins. Inside
the capsid, the viral polymerase converts pgRNA into single
stranded DNA. This reverse transcription initiates from a specific
tyrosine residue in the polymerase protein, which thereby becomes
covalently linked to the 59-end of nascent minus-strand DNA
[3,4,5]. Subsequent synthesis of the complementary second strand
results in the formation of relaxed circular DNA (rcDNA) in which
both strands partially overlap, and a fraction of double strand
linear DNA which arises if circle formation does not properly
proceed [6,7]. Furthermore, some capsids contain smaller
genomes that originate from reverse transcription of various
spliced forms of pgRNA [8,9]. Such capsids containing spliced
genomes are usually present at low frequency compared to those
with full-length DNA.
Much of our knowledge of the HBV life cycle has been obtained
from comparative studies with the distantly related duck hepatitis
B virus (DHBV) which is endemic in ducks [10,11]. DHBV
replication is commonly studied in the chicken liver tumour
derived LMH cell line [12,13]. DHBV capsids made in the
cytoplasm of transfected LMH cells are either secreted into culture
supernatant or transported to the cell nucleus where the viral
genome is released and converted into covalently closed circular
DNA (cccDNA) [14]. Such intracellular recycling of viral genomes
also occurs in HepG2 cells that are transfected with HBV coding
plasmid. The efficiency of cccDNA formation in HBV producing
HepG2 cells, however, is much lower than in DHBV synthesizing
LMH cells. Human cells instead accumulate rcDNA in the nucleus
that is released from the capsid and detached from the polymerase
protein [15,16,17]. In addition, there are HBV capsids in the
nucleus of HepG2 cells that contain genomes, which are shortened
and lack sequences in the core protein coding region. Further-
more, HepG2 cell nuclei harbour almost full-length DNA that is
not protected in viral capsids but is nevertheless connected with
polymerase protein.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37248To define the contribution of virus versus host cell in the
genome recycling pathway, we have previously performed cross-
species transfection experiments in which DHBV was expressed in
human HepG2 and HBV in chicken LMH cells. We found that
DHBV produces high amounts of cccDNA not only in LMH cells
but also in HepG2 cells. On the other hand, the cccDNA levels of
HBV were low, both in HepG2 and in LMH cells [17]. Thus, low-
level genome recycling is an intrinsic feature of HBV, rather than
a property of the cell line in which the virus replicates. During our
previous investigation, we further noticed that HBV capsids from
cytoplasm of LMH cells contain genomes with cccDNA-like
electrophoretic mobility, in addition to those DNA forms that are
commonly seen in HepG2 cells. As cccDNA is not expected to be
present in viral capsids, we sought to characterize this particular
DNA in more detail. Here, we report that the respective genomes
are not cccDNA, but instead 2.0 kb double strand linear molecules
derived from spliced transcripts. We show that LMH cells produce
exceptionally high amounts of spliced RNA, explaining the high
abundance of splicing-derived DNA in HBV capsids from the
avian cell line. Sequencing of two additional, less prominent
splicing products revealed them to be identical with those
previously found in human cells, and mutation of the common
splice acceptor site abolished splicing in HepG2 and LMH cells.
The pattern of viral DNA obtained in the avian cell line, was
nevertheless different, and many of the HBV particles from
cytoplasm of LMH cells contained shortened genomes that are not
derived from spliced RNA and lack sequences in the core protein
coding region. In this respect, they are similar to those genomes
previously discovered in the nucleus of HepG2 cells. In addition,
there were almost full-length genomes in cytoplasm of LMH cells
that are connected with polymerase protein but not protected in
viral capsids. Thus, two features of HBV replication that appear to
be confined to the nucleus of HepG2 cells are found in the
cytoplasm of LMH cells.
Materials and Methods
Cell culture and transfection
Chicken LMH cells and human HepG2 cells (both obtained
from American Type Culture Collection) were cultured in Iscove’s
Modified Dulbecco’s Medium (Gibco) supplemented with 10%
foetal calf serum, 100 U/ml of streptomycin and 100 mg/ml
penicillin. Culture dishes were coated with rat-tail collagen (BD
Biosciences) which facilitates more uniform growth and distribu-
tion of HepG2 cells. To assure identity of the cell lines, we
confirmed their species origin by amplification and partial
sequencing of the mitochondrial 16S rRNA genes. Furthermore,
short tandem repeat authentication of HepG2 chromosomal DNA
was done, yielding a profile identical to the one listed by the
American Type Culture Collection. Transfection was done with
6 ml of TransIT-LT1 liposomal reagent (Mirus Bio) and 2 mgo f
plasmid DNA per well of a 6 well culture dish.
The plasmids, applied in this study, are derived from HBV
subtype ayw and harbour an over-length genome, which enables
transcription of authentic pgRNA either from the endogenous
core promoter or from the CMV promoter [18,19,20]. To
abrogate splicing of HBV transcripts, the adenine residue at
position 1769 relative to the core start codon was replaced by
cytosine. This A1769C mutation does not change the amino acid
sequence of the viral polymerase, and has no effect on hepatitis B
surface protein, which is encoded on a second, overlapping
reading frame. Chicken LMH cells do not synthesize detectable
levels of surface protein coding RNA. Thus, transfected LMH cells
do not secrete enveloped HBV particles. To allow for comparison
with HepG2 cells, which otherwise secrete rcDNA containing
capsids into culture supernatant, we introduced two additional
nucleotide substitutions (C1399A and T1438C) which prevent the
synthesis of surface proteins. These two mutations do not alter the
polymerase protein and have no effect on splicing of pgRNA [21].
The plasmids were grown in E.coli strain, positive for Dam-
methylation to enable digestion of plasmid DNA with restriction
enzyme DpnI.
Preparation of viral DNA and RNA
Three days after transfection, the cells were detached by trypsin
treatment, resuspended in culture medium and collected by
centrifugation. The cell pellets were resuspended in 0.5 ml of lysis
buffer (140 mM NaCl, 1.5 mM MgCl2, 50 mM Tris-HCl
[pH 8.0] and 0.5% Nonidet P-40). Cell nuclei were subsequently
removed by centrifugation and the cytoplasm containing super-
natant was treated with 30 units of micrococcal nuclease (New
England BioLabs) for 2 hours at 37uC in the presence of 2 mM
CaCl2. Then, micrococcal nuclease was inactivated by adding
EDTA to a final concentration of 5 mM and the sample was
digested with 0.5 mg/ml Proteinase K in the presence of 0.5%
SDS for 1 hour at 56uC. Afterwards, RNase A (10 mg/ml) was
added and viral DNA was extracted twice with Tris-buffered
phenol/chloroform/isoamyl alcohol (25/24/1) and once with
chloroform. Precipitation was done with ethanol and the DNA was
finally dissolved in 50 ml of 10 mM Tris-HCl [pH 8.0]. The DNA
samples were treated with Plasmid safe DNase (Epicentre
Biotechnologies), or digested with restriction enzyme DpnI (New
England Biolabs) or denatured by heating at 95uC for 5 minutes,
as indicated in the respective experiments.
For complete removal of cytoplasmic capsids, HepG2 cell nuclei
were purified by sucrose gradient centrifugation. In brief, the cells
were harvested as described above and dissolved in 4.0 ml of low
sucrose buffer (0.32 M sucrose, 3 mM CaCl2, 2 mM magnesium
acetate, 1 mM dithiothreitol, 10 mM Tris-HCl [pH 8.0], 0.5%
Nonidet P-40). Subsequently, the cell lysate was gently mixed with
4.0 ml of high sucrose buffer (2.0 M sucrose, 5 mM magnesium
acetate, 1 mM dithiothreitol, 10 mM Tris-HCl [pH 8.0]), and
loaded on top of a cushion made of 4.4 ml high sucrose buffer. All
these preparation steps were done at 4uC. Centrifugation was
performed for 45 minutes with 15,500 rpm (44,0006g) at 4uCi n
a Kontron swing-out TST41 rotor. The supernatant was sub-
sequently removed by aspiration and cell nuclei at the bottom of
the tube were resuspended in 0.4 ml lysis buffer (140 mM NaCl,
1.5 mM MgCl2, 50 mM Tris-HCl [pH 8.0], 0.5% Nonidet P-40).
This suspension was mixed with 30 units of micrococcal nuclease
and incubated for 6 hours at 37uC in the presence of 2 mM CaCl2
before DNA extraction was done, as described above.
RNA was prepared from HepG2 and LMH cells with the
RNeasy Mini columns from Qiagen. Treatment with RNase free
DNase was included during RNA preparation to remove viral
DNA and transfected plasmid. The RNA samples were separated
on 1% agarose gels containing 2% formaldehyde. The gel was
subsequently soaked in 50 mM NaOH for 20 minutes to improve
transfer of large transcripts. Northern blot hybridisation was done
with a
32P-labeled fragment obtained by digestion of HBV coding
plasmid with restriction enzyme BglII, which cuts at position 84
and 523 relative to start codon the core gene.
Southern blot detection and PCR analysis
DNA samples were loaded onto TAE-buffered 1.4% low EEO
agarose gels (BioRad). A mixture of the 3.2 kb EcoRI fragment
with the 2.0 kb and 1.2 kb EcoRI/SphI fragments of the HBV
genome served as size markers. Alternatively, the 2.7 kb pUC19
HBV Replication in Chicken LMH Cells
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HBV genome was applied as marker for 3.2 kb circular genomes.
Southern blots were probed with a mixture of the 1.4 kb EcoRI/
NcoI and the 1.8 kb NcoI/EcoRI fragment obtained from an HBV
coding plasmid. These two fragments were separated from vector
sequences by agarose gel electrophoresis and isolated from gel
slices. The corresponding probe detects both strands of the whole
HBV genome and likewise visualizes viral DNA derived from
spliced and full-length pgRNA. This probe visualizes the double-
stranded forms of the HBV genome as well as single stranded
precursor molecules.
Alternatively, hybridisation was done with
32P-labeled oligonu-
cleotides 17 reverse (59-TAAGGGTCGATGTCCATGCCC-39),
18 forward (59-AAAGAATTTGGAGCTACTGTGGAG-39), 172
forward (59-GCAATTCTTTGCTGGGG-39), 355 forward (59-
TTGGTGTCTTTCGGAGTGTG-39), 399 forward (59-AC-
CACCAAATGCCCCTATCC-39), 470 forward (59-GAAGAA-
GAACTCCCGCGCCTCGCAGACGAAG-39), 520 forward (59-
AGAAGATCTCAATCTCCGGAATCTC-39), 2307 reverse (59-
GCAGCAAAACCCAAAAGACCC-39), 2340 reverse (59-
GGCATCAACGCAGGATAACCA-39), 2385 reverse (59-
GGCGAGAAAGTGAAAGCCTGC-39), 2439 reverse (59-
CGGGCAACGGGTAAAGGTTCAGG-39), 2682 reverse (59-
CAGTTGGCAGCACAGCCTAGCAGC-39).
PCR amplification of viral DNA was done with primers 18
forward (59-AAAGAATTTGGAGCTACTGTGGAG-39) and
2855 reverse (59-CCGGCAGATGAGAAGGCACAGACCCC-
39). Twenty cycles were performed with elongation at 72uC lasting
for 3 minutes to favour the synthesis of large fragments. The PCR
fragment, arising form the predominant spliced HBV genome
species, commonly termed Sp1, was cut out from the agarose gel
and subjected to direct sequencing. Another aliquot of the PCR
products, obtained with primers 18 forward and 2855 reverse, was
digested with restriction enzyme BspEI, which cuts at genome
position 429. Fragments derived from Sp3 spliced species lack the
BspEI restriction site and therefore remain complete after BspEI
digestion. These non-digested fragments were further amplified by
semi-nested PCR with primers 18 forward and 2439 reverse (59-
CGGGCAACGGGGTAAAGGTTCAGG-39) before direct se-
quence analysis.
Alternatively, viral DNA from transfected LMH cells was
digested with restriction enzyme EcoRI, which cuts at genome
position 1280, and subsequently treated with Plasmid safe DNase.
Thus, Plasmid safe DNase removes single stranded precursor
genomes, EcoRI digested full-length rcDNA, full-length linear and
spliced linear genomes, but not the Sp14 spliced species, which
lacks the EcoRI site and forms circular molecules [22]. Amplifi-
cation was done with primer 18 forward and primer 2855 reverse,
followed by nested PCR with primer 556 forward (59-
TCCTTGGACTCATAAGGTGGG-39) and primer 2439 re-
verse. The resultant PCR fragment was subjected to direct
sequence analysis.
Results
HBV particles from transfected LMH cells contain high
amounts of spliced genomes
Viral DNA made in HBV capsids upon transfection of HepG2
cells with virus coding plasmid mainly consists of single stranded,
double strand linear and relaxed circular molecules. These DNA
forms are also found in HBV capsids from cytoplasm of transfected
LMH cells, however together with various additional DNA species
(Figure 1A). Among those, the most prevalent co-migrates with
a 3.2 kb super helical plasmid, which served as a marker for
cccDNA in our previous investigation. To test whether this
particular DNA has a circular structure, we treated viral DNA
from cytoplasm of LMH cells with Plasmid safe DNase, an enzyme
that selectively digests single strand and double strand linear DNA
but not double strand circular molecules. As expected, the rcDNA
was completely resistant to Plasmid safe DNase digestion. Other
nucleic acids, including those molecules co-migrating with the
3.2 kb marker plasmid, disappeared when incubated with in-
creasing amounts of the enzyme (Figure 1A). Thus, we conclude
that the novel DNA species, abundantly present in HBV capsids
from transfected LMH cells, is not of circular structure.
Next, we compared the electrophoretic mobility of viral DNA
from LMH cells with that of linear marker fragments. This
analysis revealed that the predominant DNA species co-migrates
with a 2.0 kb restriction fragment (Figure 1B, left panel).
Denaturation of the sample before gel loading disclosed two
major viral DNA forms: the first co-migrated with the denatured
3.2 kb marker fragment, the second with the denatured 2.0 kb
marker fragment (Figure 1B, right panel). This result is consistent
with HBV capsids from LMH cells containing primarily 3.2 kb
and 2.0 kb viral genomes. The more complex pattern seen in the
non-denatured sample is due to the presence of single stranded
precursor forms of the 3.2 kb and 2.0 kb genomes. In addition,
there is a signal migrating between the 3.2 kb and 2.0 kb marker
fragments. This particular DNA species will be discussed in more
detail, later.
We reasoned that the 2.0 kb species might be a spliced variant
of the HBV genome. Therefore, we performed PCR analysis with
primers spanning almost the entire HBV genome. The main
amplification product obtained with viral DNA from LMH cells
was significantly smaller than the reference fragment amplified
from cloned DNA (Figure 1C). Sequence analysis revealed that the
PCR product was derived from a viral genome in which a 1.2 kb
fragment, ranging from position 547 to position 1771 relative to
the core start codon, was deleted (see map of the HBV genome in
Figure 1D). Such 2.0 kb genomes are known to be generated also
in human cells if a spliced variant of pgRNA, commonly termed
Sp1, is encapsidated and converted into DNA [22,23].
Selective amplification and sequence analysis of two additional
faint PCR signals, visible in Figure 1C, revealed that these
products are derived from spliced genomes in which the donor
sites localize to position 167 and 1085, respectively, with the
common acceptor site being at position 1771 (see map of the HBV
genome in Figure 1D). The same spliced genomes, termed Sp3
and Sp14, also exist in human cells [22,23]. The Sp14 species has
been reported to generate a circular molecule, which is expected to
resist Plasmid safe DNase digestion. A faint signal, most likely
representing the Sp14 species, was indeed visible upon strong
exposure of the Southern blot of Figure 1A, see lower panel. These
data indicate that pgRNA splicing, as such, is similar in human
and avian cells, but in LMH cells, there is either preferential
packaging of spliced transcripts or the extent of RNA splicing itself
is higher than in human cells, especially for the Sp1 species.
Enhanced splicing of pgRNA in avian cells gives rise to
abundant spliced viral DNA
The CAGG consensus sequence at position 1768 to 1771 in the
HBV genome represents a common splice acceptor site, shared by
various splicing products. We reasoned that mutating this site
should greatly reduce splicing and in turn promote the formation
of full-length genomes in LMH cells. To test the assumption, we
replaced the adenine residue at position 1769 in the HBV genome
for a cytosine residue (A1769C). The acceptor site in the HBV
genome localizes to the middle of the polymerase-coding gene.
HBV Replication in Chicken LMH Cells
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acid sequence and function of polymerase. According to a previous
report, splicing levels in human hepatoma cells strongly depend on
the promoter driving transcription of pgRNA [22]. To assess for
similar promoter effects in avian cells, we additionally tested
a splicing-competent HBV plasmid in which the endogenous core
promoter was substituted by the immediate early promoter of
cytomegalovirus (CMV).
First, we compared the relative amounts of spliced versus full-
length pgRNA in HepG2 and LMH cells. To this end, we
performed Northern blot analysis, using a probe specific to the 59-
end of pgRNA. According to scanning of the Northern blot signals
by phosphor imager, the amount of full-length pgRNA is about
three times higher in CMV compared to HBV promoter plasmid
transfected HepG2 cells (Figure 2A, left panel). Spliced transcripts
were detectable in HepG2 cells that were transfected with splicing-
competent HBV promoter plasmid, but the corresponding signal
was at least two times weaker than the signal of full-length pgRNA.
Transfection of the CMV promoter plasmid, however, strongly
increased splicing levels in the human cell line and made the
spliced transcripts slightly more abundant than full-length pgRNA.
This result is accordance to a report recently published by
Abraham et al., 2008.
Figure 1. Identification of spliced HBV genomes in transfected LMH cells. The plasmid transfected is coding for wild type HBV with the
natural core promoter driving transcription of pgRNA. Viral DNA was prepared from cell cytoplasm that was treated with micrococcal nuclease to
remove the transfected plasmid. (A) Viral DNA from transfected LMH cells was incubated with increasing amounts of Plasmid safe DNase and
visualized by Southern blot analysis using a
32P-labelled probe covering both strands of the whole HBV genome. A circular 3.2 kb plasmid, which
migrates at the position of cccDNA, served as marker (M). Positions of relaxed circular (RC), double strand linear (DL) and single stranded (SS) viral
DNA are indicated. Viral DNA from cytoplasm of transfected HepG2 cells is shown as reference. The lower panel is a strong exposure of the blot to
visualize the Sp14 spliced DNA which is resistant to Plasmid safe DNase digestion. (B) Viral DNA from transfected LMH cells and linear marker
fragments were denatured by heating before gel electrophoresis. The left panel shows non-denatured DNA for comparison. The positions of linear
size marker (M) fragments are indicated. (C) Viral DNA was amplified with primers binding at genome position 18 and 2855 relative to the core start
codon. Plasmid (Pla) containing the full-length HBV genome served as reference template. Amplification products derived from full-length HBV
genome and the predominant spliced species (Sp1) are indicated. Less prominent amplification products, representing Sp3 and Sp14 spliced species,
are also indicated. (D) The diagram shows a map of the HBV genome with the core, polymerase and surface coding sequences drawn as rectangles.
The core gene is presented twice to indicate that the viral genome has a circular structure. The start codon of the core protein coding gene is position
1 in the here applied nomenclature with the whole HBV genome consisting of 3182 nucleotides. At genome position 1280, there is an EcoRI
restriction site, which serves as point of reference in other commonly applied nomenclature. Arrows below symbolize spliced and full-length pgRNA.
The dashed lines illustrate the intron sequences that are removed in Sp14, Sp1 and Sp3 spliced species. The corresponding splice donor sites are at
position 167, 547 and 1085 while the common splice acceptor site is at position 1771. If numbering starts with the EcoRI restriction site, the common
splice acceptor site will be position 487 and the splice donor sites will be position 2065, 2445 and 2983, according to Abraham et al., 2008.
doi:10.1371/journal.pone.0037248.g001
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pgRNA, if transfected with splicing-competent HBV and CMV
promoter plasmid, but the amount of full-length pgRNA increased
by a factor of two upon transfection of splicing-deficient HBV
promoter plasmid (Figure 2A, right panel). Spliced RNA was
strongly present in splicing-competent HBV promoter plasmid
transfected LMH cells (more than twice as much as full-length
pgRNA), and was about five times more abundant than full-length
pgRNA in CMV promoter plasmid transfected cells. Thus,
chicken LMH cells produce considerably more spliced than full-
length pgRNA. Especially, the Sp1 spliced species is strongly
increased while others are hardly visible in LMH cells. Further-
more, the CMV promoter enhances splicing levels not only in
human HepG2 but also in chicken LMH cells. Mutational
suppression of splicing, on the other hand, results in a significant
increase of full-length pgRNA in the avian cell line. Comparing
viral RNA from cytoplasm with encapsidated RNA from
immunoprecipitated capsids indicated that relative packaging of
spliced molecules is similar in HepG2 and LMH cells (see Figure
S1). Therefore, high levels of spliced DNA in HBV capsids from
LMH cells are primarily due to the enhanced splicing of viral
RNA between genome position 547 and 1771.
Next, we prepared viral DNA from transfected HepG2 and
LMH cells, and we performed PCR analysis using primers
spanning the intron sequences. In HepG2 cells, splice-specific
amplification products were detectable only upon transfection of
splicing-competent HBV and CMV promoter plasmids but not in
case of splice-deficient HBV promoter plasmid transfection
(Figure 2B, left panel). In LMH cells, very strong signals were
obtained for splice-derived products upon transfection of splicing
competent plasmids, and those signals were absent in case of
splice-deficient plasmid transfection (Figure 2B, right panel).
Hence, the single A1769C mutation efficiently suppressed pgRNA
splicing and subsequent synthesis of viral DNA from spliced
transcripts in avian and human cells.
Furthermore, we performed Southern blot analysis to visualize
directly viral DNA made in the respective capsids. In HepG2 cells,
no major difference in quantity and pattern of replicative DNA
was seen upon transfection with splice-deficient versus splicing-
competent HBV promoter plasmid (Figure 2C, left panel). Use of
the CMV promoter plasmid enhanced replication levels in HepG2
cells, but the pattern of viral DNA remained largely unchanged. In
LMH cells, splice-derived DNA was clearly detectable upon
transfection of splicing-competent HBV and CMV promoter
plasmids. The corresponding signal was absent from cells that
were transfected with the splice-deficient construct (Figure 2C,
right panel). Surprisingly, much of the viral DNA from cytoplasm
LMH cells, that were transfected with splice-deficient HBV
promoter plasmid, migrated between the 3.2 kb and 2.0 kb
marker fragments (see arrow in Figure 2C, right panel). Such DNA
is also detectable in case of splicing-competent plasmid trans-
fection, but becomes evident more clearly in the absence of
splicing.
Figure 2. Comparison of HBV replication in human HepG2 and
chicken LMH cells. The transfected plasmids are coding for splice-
deficient and splicing-competent virus (+/2 splicing) with either the
natural HBV core promoter or the CMV promoter driving transcription
of pgRNA. The here applied plasmids additionally have the surface
protein coding sequence mutated to abrogate secretion of rcDNA
containing particles in human HepG2 cells. (A) Viral RNA from
cytoplasm of HepG2 and LMH cells was visualized by Northern blot
analysis. Hybridization was done with a probe specific to the 59-end of
spliced and full-length pgRNA (genome position 84 to 523). This probe
corresponds to the core protein coding sequence (see map of
Figure 1D) and does not detect surface protein coding transcripts.
The 28S and 18S ribosomal RNA served as size marker. Positions of full-
length pgRNA and predominant Sp1 spliced species are indicated. The
asterisk denotes another transcript probably representing Sp14 spliced
RNA abundantly made in HepG2 cells. (B) Viral DNA from transfected
HepG2 and LMH cells was amplified with primers spanning the intron
sequence in the HBV genome. PCR products derived from full-length
genomes and the predominant Sp1 spliced species are indicated. (C)
Viral DNA was visualized by Southern blot hybridisation with a probe
that covers both strands of the whole HBV genome, and likewise
detects viral DNA derived from spliced and full-length pgRNA. Positions
of relaxed circular (RC), double strand linear (DL), single stranded (SS)
and spliced viral DNA are indicated. The arrow points to viral DNA
migrating between the 3.2 kb and 2.0 kb marker fragments. Note that
such DNA is also present in splicing-competent HBV and CMV promoter
plasmid transfected LMH cells, albeit scarcely visible in the here
presented exposure. The corresponding signal, however, is more clearly
seen in previous Figure 1B. (D) Viral DNA was denatured by heating
before electrophoresis and visualized by hybridisation with a mixture of
32P-labelled forward oligonucleotides that are complementary to the 39-
end region of minus-strand DNA (genome position 18, 172, 355, 399,
470 and 520 in the core protein coding sequence; see map of
Figure 1D). Positions of full-length and Sp1 spliced genomes are
indicated.
doi:10.1371/journal.pone.0037248.g002
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we denatured aliquots of each sample prior to electrophoresis.
Thus, double strand mature genomes and single stranded
precursor molecules will migrate at the same position in the gel.
Subsequent Southern blot hybridisation was done with forward
oligonucleotides binding close to the 39-end of minus strand DNA
in order to visualize spliced and full-length genomes with equal
efficiency. As shown in the left panel of Figure 2D, HBV promoter
plasmid transfected HepG2 cells predominantly produce full-
length genomes and the spliced genomes are scarcely visible
because of their low abundance. The spliced genomes, however,
are clearly detectable when instead the CMV promoter construct
was used. In LMH cells, by comparison, very strong signals are
seen for the spliced genomes, especially in case of CMV promoter
plasmid transfection (Figure 2D, right panel).
Quantitation of the Southern blot signals by phosphor imager
revealed that the CMV promoter enhances synthesis of full-length
DNA by a factor of three in human HepG2 cells. The full-length
genomes are about three times more abundant than the spliced
genomes in CMV promoter plasmid transfected HepG2 cells. In
LMH cells, this ratio is reversed, with about two-times more
spliced than full-length genomes for the HBV promoter construct,
and about five-times more spliced than full-length genomes for the
CMV promoter construct. Mutation of the splice-acceptor site, on
the other hand, increases the amount of full-length genomes by
a factor of five in the avian cell line. Altogether, these results
demonstrate that enhanced splicing of pgRNA in LMH cells gives
rise to increased amounts of spliced DNA. High level of splicing in
chicken LMH cells, on the other hand, reduces the amount of full-
length pgRNA and thereby diminishes the number of viral
particles replicating the full-length HBV genome.
HBV capsids from cytoplasm of LMH cells contain
shortened viral genomes
As mentioned above, much of the DNA present in viral particles
from LMH cells migrates between the 3.2 kb and 2.0 kb marker
fragments (see arrow in the right panel of Figure 2C). Such
migration pattern might be due to incomplete elongation of plus-
strand DNA molecules, as commonly seen with HBV particles
from human blood. Alternatively, the characteristic profile may
relate to the absence of specific DNA sequences as recently
observed with HBV capsids from the nucleus of HepG2 cells [17].
As shown in Figure 3A, the most prominent DNA species in HBV
capsids from HepG2 cell nucleus display the same electrophoretic
mobility as those DNA molecules from cytoplasm of LMH cells
that migrate between the 3.2 kb and 2.0 kb marker fragments. We
have recently reported that HBV genomes from nucleus of HepG2
cells lack sequences in the core protein coding region, and these
sequences may also be absent in viral DNA from cytoplasm of
LMH cells.
To test for this hypothesis, we visualized viral DNA from splice-
deficient HBV plasmid transfected LMH cells by Southern blot
hybridisation with oligonucleotides binding near the 39-end and
near the 59-end of plus-strand DNA, respectively. As expected,
both probes detect rcDNA which co-migrates, after heating, with
the 3.2 kb denatured marker fragment (Figure 3B). This rcDNA is
derived from capsids containing completely mature, full-length
HBV genomes. The 39-end specific probe additionally detects
DNA migrating between the 3.2 kb and 2.0 kb marker fragments
(see arrow in left panel of Figure 3B). Yet, such DNA is scarcely
visible with the 59-end specific probe, which instead visualizes
a faint smear of signals in the corresponding area (Figure 3B, right
panel). Denaturation of the DNA samples before gel electropho-
resis revealed that most of the plus-strand molecules that are
detected with the 39-end specific probe, are heterogeneous in size
with some of them being shorter than 2.0 kb (Figure 3B, left
panel). As the probe binds to the 39-end, the respective plus-strand
molecules must lack sequences at the 59-end, which corresponds to
the core protein coding region.
We speculated that the lack of sequence in the core coding
region might be due to selective degradation of the respective
region in the HBV genome during DNA preparation, which
involves nuclease treatment of viral capsids. To test for this
possibility, we prepared viral DNA with and without micrococcal
nuclease treatment of cytoplasmic lysates. In addition, we asked
whether the polymerase protein is linked with the viral genome.
For this reason, protease treatment was omitted with an aliquot of
each sample, which results in partitioning of protein-linked nucleic
acid into the organic phase during phenol extraction and therefore
loss of the respective genomes during DNA preparation.
Preparation of viral DNA from splice-deficient HBV plasmid
transfected LMH cells by the standard procedure, which includes
nuclease treatment of cytoplasmic lysate and subsequent protease
digestion, resulted in the typical pattern of DNA with a prominent
signal migrating between the 3.2 kb band 2.0 kb marker
fragments (see arrow in Figure 3C). These signals are much
weaker when protease treatment was omitted before phenol
extraction, indicating that viral genomes that are protected inside
the capsid are covalently linked with polymerase protein. Omitting
micrococcal nuclease treatment before protease digest and phenol
extraction resulted in a slight upward shift of the major signal close
to the position of the 3.2 kb marker fragment. Therefore, the
respective HBV genomes were not properly protected in viral
capsids and were at least partially accessible to nuclease digestion.
Omitting additionally the protease digest strongly diminished the
signals close to the 3.2 kb marker fragment. Thus, those genomes
that are not properly protected in viral capsids, are nevertheless
linked with polymerase protein. HBV genomes migrating close to
the 3.2 kb marker fragment may have been converted into
shortened genomes during nuclease treatment because of partial
degradation. Alternatively, the nuclease enzyme may have
selectively removed those species migrating close to the 3.2 kb
linear marker fragment, rendering the shortened genomes more
clearly visible.
To distinguish between these two alternatives, we prepared viral
DNA from cytoplasm of LMH cells with or without nuclease
treatment. The purified DNA was denatured before gel electro-
phoresis and subsequently visualized by hybridisation with
oligonucleotides binding to the 39-prime end of plus-strand
DNA. In this experiment, we also included viral DNA from
cytoplasm of HepG2 cells, for reference. As seen in Figure 3D,
there are various shortened plus-strand molecules visible that
migrate clearly faster than 3.2 kb full-length DNA. These plus-
strand molecules are present both in the micrococcal nuclease
treated and in the non-treated sample. Thus, the shortened
genomes are most likely not generated during nuclease treatment.
Instead, they are a priori present in HBV capsids from cytoplasm
of LMH cells. Remarkably, shortened genomes are also detectable
in denatured viral DNA from cytoplasm of HepG2 cells. However,
the corresponding signals are very weak compared to the signal of
3.2 kb full-length genomes and compared to the respective signals
in LMH cells.
Discussion
Splicing occurs in most and potentially all natural HBV
variants. Yet, the importance of splicing during HBV infection
remains elusive [24]. Usually, less than 10% of the viral DNA
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splicing [25,26]. HBV particles containing spliced genomes
probably do not contribute to virus amplification, because essential
protein coding sequences are lost during splicing. Therefore,
splicing is of potential disadvantage for virus reproduction and
needs to be kept at tolerable levels in the infected liver cells.
Spliced RNA is also made in human hepatoma cells that are
transfected with HBV coding plasmids [22,27]. With the natural
HBV core promoter, the amount of spliced RNA is significantly
less than that of full-length pgRNA. Transfection of CMV
promoter plasmids, however, increases the splicing levels and
spliced transcripts are present at slightly higher amount than full-
length pgRNA. Nevertheless, there are clearly less spliced than
full-length DNA genomes present in viral capsids from CMV
promoter plasmid transfected HepG2 cells. The apparent
discrepancy in the relative levels of spliced RNA and DNA can
be explained by the fact that HBV polymerase preferentially binds
the full-length pgRNA from which the protein was translated [28].
Thus, the polymerase favours encapsidation of full-length pgRNA,
provided that both transcripts arise from the same template.
However, spliced and full-length pgRNA have equal chances to
enter viral capsids if the polymerase coding RNA and the pgRNA
to be encapsidated are transcribed from two different plasmids.
Therefore, up to 50% of viral DNA is derived from spliced
Figure 3. Detection of shortened HBV genomes in the cytoplasm of LMH cells. Transfection was done with a plasmid coding for splice-
deficient virus with the natural HBV core promoter driving transcription of pgRNA and the surface protein coding sequence mutated. (A) Viral DNA
from cytoplasm of LMH cells was compared with viral DNA from HepG2 cell nuclei and HepG2 cytoplasm. Preparation of viral DNA involved nuclease
treatment of cytoplasmic lysates and purified cell nuclei. Numbers below indicate relative amounts of DNA loaded in the respective lanes.
Hybridisation was done with a probe encompassing both strands of the whole HBV genome. The arrow points to a prominent DNA species obtained
both in cytoplasm of LMH cells and nucleus of HepG2 cells. (B) Viral DNA from transfected LMH cells was denatured (+/2 denat) by heating before
gel loading, as indicated. Hybridisation was done with
32P-labelled oligonucleotides detecting either the 39-end or the 59-end of plus-strand DNA at
genome positions 2682 and 17 (see map of the HBV genome in Figure 1D). Positions of the 3.2 kb and 2.0 kb marker fragments are indicated. The
arrow points to viral genomes migrating between these marker fragments. (C) Viral DNA was prepared from cytoplasm of transfected LMH cells with
or without micrococcal nuclease (+/2 MN) treatment and with or without protease (+/2 ProtK) digestion done before phenol extraction. The purified
DNA was digested with restriction enzyme DpnI, which selectively cuts transfected plasmid (Pla) into multiple short fragments. Southern blot
hybridisation was done with a probe covering both strands of the whole HBV genome. This probe also detects several DpnI fragments of transfected
plasmid DNA. (D) Viral DNA was prepared from cytoplasm of HepG2 and LMH cells with or without micrococcal nuclease (+/2 MN) treatment.
Purified DNA was subsequently digested with restriction enzyme DpnI and denatured by heating before gel electrophoresis. Southern blot
hybridisation was done with a mixture of
32P-labeled oligonucleotide complementary to the 39-end of plus-strand DNA at genome position 2307,
2340, 2385, 2439 and 2682. These five oligonucleotides were combined to enhance sensitivity. The vertical lane on the right side indicates shortened
plus-strand molecules. The probe detects a 0.8 kb DpnI fragment of the transfected plasmid (Pla) if micrococcal nuclease treatment is not done.
doi:10.1371/journal.pone.0037248.g003
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promoter plasmids, as previously reported by Abraham et al.,
2008.
Most studies on HBV replication in human hepatoma cells do
not pay specific attention to the spliced DNA molecules because
they are usually not visible in the background of signals from
nascent full-length genomes. Detection of spliced genomes,
however, needs to be taken into account if trans-complementation
experiments are done and if CMV promoter plasmids are applied.
In addition, the spliced DNA becomes especially evident with
specific mutations in the carboxyterminal domain of the HBV core
protein. The phenotype of these mutants is due to destabilisation
of full-length pgRNA containing capsids and selective synthesis of
short genomes derived from spliced transcripts [29,30]. This
phenomenon was initially discovered with CMV promoter
plasmids and was not noticed in other studies, presumably because
HBV promoter plasmids were applied in the respective investiga-
tions [31,32,33].
Notably, complete absence of viral genomes derived from full-
length pgRNA has only been observed so far, if nearly half of the
carboxyterminal domain of the HBV core protein was deleted or if
three serine phosphorylation sites in the carboxyterminal domain
were collectively mutated [29,30]. Other mutants displayed an
intermediary phenotype with some tendency to get less full-length
genomes than with wild type. This phenomenon is generally
thought to reflect a role of serine phosphorylation and de-
phosphorylation during elongation of viral DNA [34]. However,
preferential synthesis of shortened genomes, like those abundantly
present in LMH cells, may also explain the phenotype. Thus, it
might be revealing to compare the replication of HBV core
mutants in HepG2 and LMH cells to understand more clearly the
effects of mutations in the carboxyterminal domain on synthesis of
viral DNA. In addition, it might be worthwhile to examine more
extensively the core protein made in LMH cells for the presence of
post-translational modifications, which probably requires mass
spectrometry, as protein gel electrophoresis does not disclose any
migration differences in comparison with HBV core protein from
HepG2 cells (see Figure S2).
High abundance of spliced genomes in HBV capsids from
transfected LMH cells is primarily due to excessive splicing of
pgRNA. Especially, the Sp1 spliced species is strongly enhanced in
the avian cell line. Other spliced transcripts, like the Sp3 and Sp14
species, are also made but they are not profoundly increased. HBV
replication in LMH cells clearly illustrates that the synthesis of
spliced genomes occurs at the expense of full-length genomes. In
human HepG2 cells, such competition is less evident and the
splicing process remains at low enough levels to permit sufficient
virus production. Nonetheless, it is puzzling why splicing of HBV
transcripts happens at all. Our investigation shows that splicing
can be abolished with a single nucleotide exchange. Notably, the
A1769C mutation, examined in this study, has no effect on viral
protein sequences. Therefore, one would expect that an equivalent
mutation occurs as a common variant in HBV infected patients.
Most HBV sequences deposited to GenBank, however, possess the
splice acceptor site with an adenine at position 1769. The presence
of splice sites in natural virus variants strongly argues for an
important role of splicing during HBV infection, and exploring the
relevance of this process in the HBV life cycle will be a major
challenge of future research.
Splicing also occurs with DHBV transcripts. However, the
splice sites in the DHBV genome localize to positions different
from those in the HBV genome [35]. Nevertheless, splicing of
DHBV transcripts also disrupts the polymerase coding sequence
and reduces the amount of full-length pgRNA available for
synthesis of infectious viruses. Interestingly, a secondary structure,
caused by complementary sequences near the splice donor and
acceptor sites, protects DHBV pregenomic RNA from excessive
splicing [36]. Such complementary sequences are not evident in
the HBV genome and it is not yet known whether other control
mechanisms exist that potentially down-regulate splicing of HBV
transcripts in human cells.
Increased splicing of HBV transcripts in LMH cells may simply
be due to better conformance of the avian spliceosome with the
respective sequences in the HBV genome, in particular regarding
the Sp1 splice donor site. However, the 59-end sequences of U1
small nuclear RNA, which recognize splice donor sites, are
identical in human and chicken [37]. Alternatively, a specific
control mechanism that down-regulates splicing of HBV tran-
scripts in human cells might be absent in avian cells. Future
studies, comparing RNA synthesis in HepG2 and LMH cells, may
help to reveal a control mechanism that down-regulates splicing of
HBV transcripts in the natural host. Of note, the prevention of
excessive splicing may represent a hitherto little-thought-of factor
restricting the species tropism of HBV.
We have recently shown that DHBV replicates in human
HepG2 cells with the same pattern and efficiency as in chicken
LMH cells. Human HBV, on the other hand, is able to replicate in
chicken LMH cells, but here the viral DNA looks different from
viral DNA obtained in HepG2 cells. The distinct pattern of viral
DNA is primarily due to enhanced splicing of pgRNA in the avian
cell line. Furthermore, many of the HBV capsids from cytoplasm
of transfected LMH cells contain shortened genomes that lack
sequences in the core protein coding region. So far, it is not clear
how the shortened genomes arise and why they are so abundant in
chicken LMH cells. One possible explanation for the observed
absence of DNA sequences in the core protein coding region is
premature stop of minus-strand elongation and subsequent start of
plus-strand synthesis from RNA fragments that were not fully
digested by the RNase H activity of HBV polymerase. Re-
markably, shortened genomes can also be found in cytoplasm of
HepG2 cells. However, they are present there at very low
abundance, and for this reason probably remained undetected
until now.
Furthermore, there are capsids in the cytoplasm of LMH cells
that do not protect the viral genome. The corresponding
molecules migrate slightly beneath 3.2 kb double strand linear
indicating that they represent genomes in which plus-strand
synthesis has initiated upstream of the core protein reading frame
or at least the complementary minus-strand is fully elongated.
These genomes are lost if DNA preparation includes nuclease
treatment of cytoplasmic lysate. So far, it is not clear whether non-
protected genomes also exist in cytoplasm of HepG2 cells. At least,
omission of nuclease treatment does not make an obvious
difference in the pattern of viral DNA obtained from cytoplasm
of human HepG2 cells (see Figure 1B in Ko ¨ck et al., 2010).
Nuclease treatment, however, makes a clear-cut difference
regarding the viral DNA obtained from the nucleus of HepG2
cells: HepG2 cell nuclei, first, contain rcDNA that is released from
the capsid and detached from the polymerase protein. Such
rcDNA molecules are digested if HepG2 cell nuclei are treated
with micrococcal nuclease enzyme. Second, there are viral
genomes that migrate close to 3.2 kb double strand linear DNA.
These genomes are likewise not protected from nuclease digestion
but they are still connected with polymerase protein (see Figure
7A, right panel in Ko ¨cket al., 2010). Third, there are genomes that
migrate clearly faster than 3.2 kb double strand linear, are
protected in viral capsids and are connected with polymerase
protein (see Figure 7B, right panel in Ko ¨ck et al., 2010). We
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full-length genomes that were partially digested in the core protein
coding region during micrococcal nuclease treatment of HepG2
cell nuclei. The here presented data, however, indicate that such
genomes also exist in cytoplasm of HepG2 cells, and that they are
present even if nuclease treatment is not done. Thus, they are most
likely not generated during nuclease treatment of HepG2 cell
nuclei. Instead, they become clearly visible because other HBV
genomes that are not protected in viral capsids are removed by the
nuclease enzyme.
Interestingly, incomplete protection of viral genomes in HepG2
cell nuclei is found only if HBV surface protein is absent (see
Figure S3). Chicken LMH cells do not synthesize HBV surface
RNA and thus do not produce surface proteins. So far, we have
not yet tested whether the presence of surface protein potentially
makes a difference regarding nuclease sensitivity of viral genomes
in HBV capsids from cytoplasm of LMH cells. This question will
be addressed in future studies by co-transfection of appropriate
expression plasmids coding for HBV surface proteins.
The cell nucleus is the place where the HBV capsid needs to
open for release of rcDNA and subsequent cccDNA formation.
Until now, almost nothing is known about the biochemical events
that trigger HBV capsid disassembly in the cell nucleus. The here
presented data indicate, that a process potentially reflecting capsid
disassembly in the nucleus of human HepG2 cells takes place in
cytoplasm of chicken LMH cells. In particular, the incomplete
protection of viral genomes migrating close to 3.2 kb double
strand linear may mimic the opening of HBV capsids in the cell
nucleus. Studies of HBV capsid disassembly in HepG2 cell nuclei
are limited by the low number of viral particles present there.
Cytoplasm of LMH cells, on the other hand, abundantly contains
apparently opened capsids facilitating large-scale preparation for
more extensive biochemical and structural analysis. Thus, trans-
fection of LMH cells with HBV coding plasmids may pave the way
for follow-up investigations on the mechanism of capsid disinte-
gration which is an essential prerequisite for cccDNA formation
during infection and intracellular recycling of viral genomes.
Supporting Information
Figure S1 HepG2 and LMH cells were transfected with
HBV coding plasmid having the polymerase sequence
mutated (YMHD instead of YMDD which results in
deficiency for reverse transcriptase activity). The RNA
was prepared from total cytoplasm and from HBV capsids that
were obtained by immunoprecipitation. Immunoprecipitation was
done from 300 ml cytoplasmic lysate, whereas total RNA isolation
was done from 100 ml cytoplasmic lysate. The probe detects the
59-end of spliced and full-length pgRNA. The 18S and the 28S
ribosomal RNAs served as size markers. Note that the relative
efficiencies of spliced and full-length pgRNA packaging are similar
in HepG2 and LMH cells.
(TIF)
Figure S2 HepG2 and LMH cells were transfected with
wild type HBV and with GFP coding plasmids. The GFP
protein and the HBV core protein were visualized by Western blot
analysis. Numbers below indicate relative amounts of cell lysate
loaded in the respective lane. n.t. is a non-transfected control.
Positions of size marker proteins (17 and 25 kDa) are shown on the
left side. Note that HBV core proteins from HepG2 and LMH
cells migrate at the same position in the gel. Thus, there is no
evidence of differing post-translational modification in both cell
lines, yet. The HBV core protein is translated from full-length
pgRNA and from spliced RNA causing high abundance of core
protein in LMH cells.
(TIF)
Figure S3 HepG2 and LMH cells were transfected with
splice-deficient HBV coding plasmid, in which the
surface-coding sequence was either mutated (surface-
negative) or wild type (surface-positive). Viral DNA was
prepared from micrococcal nuclease treated cytoplasm and from
micrococcal nuclease treated cell nuclei. Numbers below indicate
relative amounts of DNA loaded. The probe applied detects both
strands of the whole HBV genome. Note that cytoplasm of
surface-positive HBV producing cells harbours less rcDNA
containing capsids than cytoplasm of surface-negative HBV
producing cells; probably because rcDNA containing capsids are
secreted into culture supernatant if surface protein is present. Most
interesting, viral capids in the nucleus of surface-positive HBV
producing cells protect all genome species, whereas capsids in the
nucleus of surface-negative HBV producing cells fail to protect
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